Cadila will file for emergency use authorisation after it has submitted its vaccine to the Drugs Controller General of India
According to Nomura, the overhang of whistleblower allegations is now behind and will prefer Infosys to TCS on valuations basis
Motilal Oswal is bullish on Cadila Health has recommended buy rating on the stock with a target price of Rs 275 in its research report dated August 10, 2019.
Motilal Oswal is bullish on Cadila Health has recommended buy rating on the stock with a target price of Rs 345 in its research report dated May 29, 2019.